🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalSouth Korea Ozempic availability — 12 month update Page 7

South Korea Ozempic availability — 12 month update

greg_boulder Sat, Aug 16, 2025 at 6:58 AM 40 replies 1,750 viewsPage 7 of 8
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Sep 5, 2025 at 9:36 PM#31

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

19 19SleepFixSam, PurityPaulOR, MaxMetOK and 16 others
Reply Quote Save Share Report
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Sep 7, 2025 at 1:20 AM#32

One thing that is still open after Dr.ObesityLA’s answer:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

18 18mark_tokyo, hans_munich, jason_sac26 and 15 others
Reply Quote Save Share Report
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
Sep 8, 2025 at 5:05 AM#33
wendy_avl said:
Keep the original post as written when you update it, and add the correction underneath.

I read this differently from wendy_avl, on substance rather than tone. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

Last edited: Sep 8, 2025 at 11:05 AM
17 17HPLC_Greg, LibrarianMeg, bri_stats and 14 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Sep 9, 2025 at 8:50 AM#34
wendy_avl said:
Keep the original post as written when you update it, and add the correction underneath.

No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.

16 16JenMemphis, pat_auckland, Dr.GastroMayo and 13 others
Reply Quote Save Share Report
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Sep 10, 2025 at 12:36 PM#35
wendy_avl said:
Keep the original post as written when you update it, and add the correction underneath.

Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.

15 15PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 12 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register